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Abstract—The literature shows inconsistent evidence regarding the association between clinically assessed plantarflexor
(PF) spasticity and walking function in ambulatory persons
with multiple sclerosis (pwMS). The use of a dynamometerbased spasticity measure (DSM) may help to clarify this association. Our cohort included 42 pwMS (27 female, 15 male;
age: 42.9 +/– 10.2 yr) with mild clinical disability (Expanded
Disability Status Scale score: 3.6 +/– 1.6). PF spasticity was
assessed using a clinical measure, the modified Ashworth
Scale (MAS), and an instrumented measure, the DSM. Walking function was assessed by the timed 25-foot walk test
(T25FWT), the 6-minute walk test (6MWT), and the 12-item
Multiple Sclerosis Walking Scale (MSWS-12). Spearman rho
correlations were used to evaluate relationships between spasticity measures, measures of walking speed and endurance, and
self-perceived limitations in walking. The correlation was
small between PF spasticity and the T25FWT (PF maximum
[Max] MAS rho = 0.27, PF Max DSM rho = 0.26), the 6MWT
(PF Max MAS rho = 0.20, PF Max DSM rho = 0.21), and
the MSWS-12 (PF Max MAS rho = 0.11, PF Max DSM rho =
0.26). Our results are similar to reports in other neurologic
clinical populations, wherein spasticity has a limited association with walking dysfunction.

INTRODUCTION
Multiple sclerosis (MS) is a chronic, inflammatory
disease of the central nervous system (CNS) characterized by demyelination and loss of motor and sensory
axons within the brain and spinal cord [1]. Spasticity,
defined as a motor disorder characterized by a velocitydependent increase in tonic stretch reflexes and increased
tendon jerks resulting from disinhibition of the stretch
reflex [2], is a typical consequence of pathological
changes within the corticospinal system. Lower-limb
spasticity is believed to be a key contributor to mobility
disability in persons with MS (pwMS). As such, lowerlimb spasticity is routinely assessed in clinical practice to

Abbreviations: 6MWT = 6-minute walk test, CNS = central
nervous system, DF = dorsiflexion, DSM = dynamometerbased spasticity measure, EDSS = Expanded Disability Status
Scale, EMG = electromyography, MAS = modified Ashworth
Scale, Max = maximum, MS = multiple sclerosis, MSWS-12 =
12-item Multiple Sclerosis Walking Scale, PF = plantarflexor,
pwMS = persons with multiple sclerosis, ROM = range of
motion, RRMS = relapsing-remitting multiple sclerosis,
T25FWT = timed 25-foot walk test.
*
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document clinical disability and monitor disease progression, and therapies aimed at reducing spasticity are
employed to promote better walking in pwMS [3–4].
PwMS perceive spasticity to be related to selfreported mobility disability [5]. Nonetheless, there is
inconsistent evidence regarding the association between
lower-limb spasticity, measured using the modified Ashworth Scale (MAS) [6], and walking speed, walking
endurance, and self-perceived walking limitations. Sosnoff et al. reported on a group of 34 pwMS, 15 of whom
exhibited plantarflexor (PF) spasticity [7]. In this cohort
of pwMS, the group with PF spasticity had slower walking speed (p = 0.02), reduced walking endurance (p <
0.01), and greater self-perceived walking limitations (p =
0.04) than the group without spasticity. In contrast, we
recently reported a small relationship between PF spasticity measured using the MAS and walking speed (ρ =
0.27, p = 0.08), walking endurance (ρ = 0.20, p = 0.20),
and self-perceived walking limitations (ρ = 0.11, p =
0.48) [8]. There also were no differences in walking
speed (p = 0.34), walking endurance (p = 0.72), or selfperceived walking limitations (p = 0.64) in pwMS with
PF MAS scores greater than 0 (n = 29) compared with
pwMS with PF MAS equal to 0 (n = 13).
The MAS is the most commonly reported clinical
measure of spasticity; however, the objectivity of the
MAS has been questioned [9]. Dynamometer-based spasticity measures (DSMs), which objectively quantify
velocity-dependent resistance to passive movement, have
been developed to address the subjectivity of the MAS
[10–14]. Dynamometer-based estimates of lower-limb
spasticity have confirmed a limited association between
lower-limb spasticity, as measured using clinical scales,
and walking dysfunction in other neurologic clinical populations [10–14]. Quantifying spasticity using a DSM in
addition to the MAS may clarify the ambiguous evidence
regarding the effect of lower-limb spasticity on walking
dysfunction in pwMS. A better understanding of the association between lower-limb spasticity and walking dysfunction in pwMS is required for the development of
targeted therapeutic interventions aimed at improving
walking.
The purpose of this study was to determine the effect
of PF spasticity on walking function in pwMS by examining the relationships between clinically assessed PF
spasticity; a DSM of PF spasticity; and walking function
assessed by standardized measures of walking speed,
walking endurance, and self-perceived walking limita-

tions. We hypothesized based on our previous work in
this cohort [8], and based on studies of walking dysfunction in people with other CNS conditions, that there is a
limited association between PF spasticity, whether measured clinically or using a dynamometer, and walking
speed, walking endurance, and self-perceived walking
limitations in pwMS.

METHODS
Participants
Study participants included 45 ambulatory pwMS.
All participants were recruited through the Multiple Sclerosis Clinic at Saint Louis University, The John L. Trotter
Multiple Sclerosis Clinic at Washington University
School of Medicine, and the Gateway chapter of the
National Multiple Sclerosis Society. Participants were
included (1) if they had a diagnosis of MS from a boardcertified neurologist, including relapsing-remitting MS
(RRMS), secondary progressive MS, and primary progressive MS; (2) if they were 18 to 65 yr old; (3) if they
had minimal to moderate clinical disability as evidenced
by an Expanded Disability Status Scale (EDSS) score
ranging from 0.0 to 6.0, as determined by a boardcertified neurologist; and (4) if they had RRMS but were
at least 6 mo following their last clinical exacerbation of
MS. Participants were excluded if they (1) had lowerlimb orthopedic conditions that limited ambulation,
(2) were pregnant, or (3) were unable to provide
informed consent.
Data Collection
PF spasticity was measured bilaterally using the MAS
[6]. The MAS provides a rating of spasticity on a 0 to 4
scale, where 0 = no increase in muscle tone and 4 =
affected part(s) are rigid in flexion or extension. The MAS
has been found to be a reliable measure in pwMS [15].
Walking function was assessed by standardized measures of walking speed, walking endurance, and self-perceived walking limitations. The timed 25-foot walk test
(T25FWT), a component of the Multiple Sclerosis Functional Composite, is a standardized clinical measure of
short-distance maximal walking speed [16]. The 6-minute
walk test (6MWT) is a standardized clinical measure of
walking endurance [17]. The 12-item Multiple Sclerosis
Walking Scale (MSWS-12) is a self-report measure of the
effect of MS on walking ability [18]. The MSWS-12
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provides a score from 0 to 100, with larger values indicating a greater perception of walking difficulty due to MS.
These tests were administered following standardized procedures by a physical therapist.
PF spasticity was also quantified using a Biodex System 4 dynamometer (Biodex Medical Systems, Inc; Shirley, New York). Both ankles were tested in a random
order. Each participant was placed on the dynamometer
in a semisupine position. For the tested limb, the leg was
positioned so that the knee was in full extension and supported by the dynamometer chair. The foot was placed
in the dynamometer dorsiflexion (DF)/plantar flexion
attachment, and the ankle joint center was aligned with
the center of rotation of the dynamometer. All participants were tested wearing shoes. Ankle range of motion
(ROM) limits were preestablished to allow for a total of
40 of ROM, ranging from 30 PF to 10 DF. Waist and
knee straps were used to stabilize the pelvis and lower
limb, and a foot rest provided support for the nontested
limb. For the test, the ankle was passively rotated from
PF to DF 3 times at an angular velocity of 5 °/s and 10
times at angular velocities of 20, 60, and 90 °/s [19]. Participants were instructed not to help move the lever arm
and remain relaxed while spasticity measurements were
being taken. DSMs have moderate reliability [10,12].
Bipolar surface electromyography (EMG) electrodes
(MA300 EMG system, Motion Lab Systems Inc; Baton
Rouge, Louisiana) placed on the gastroc-soleus and anterior tibialis were used to visually monitor agonist and
antagonist muscle activity, respectively, to ensure the
movement was passive. Analog torque (foot-pounds),
position (degrees), and velocity (degrees per second) signals were sampled directly from the dynamometer at a
rate of 1 kHz using a PowerLab 16/30 (ADInstruments;
Dunedin, New Zealand) and LabChart Pro version 7 software (ADInstruments) and saved directly to disk for subsequent analysis.
Data Analysis
Because the MAS includes a score of 1+, the raw PF
MAS scores were transformed to a 0 to 5 scale [20]. The
PF maximum (Max) MAS score (PF Max MAS) for each
participant was determined and used for subsequent analysis. PwMS with PF MAS scores 1.0 or more for either leg
were classified as having spasticity, whereas pwMS with
PF MAS scores less than 1.0 on both legs were classified
as not having spasticity [7].

For the DSM, data analysis was performed using
LabChart Pro version 7 and MATLAB R2011b (The
MathWorks Inc; Natick, Massachusetts). Torque angle
data were low-pass filtered (50 Hz) then processed to
correct for the effects of limb weight and gravity using an
anthropomorphic method [21]. The weight of the foot
was assumed to be 1.45 percent of the entire body weight
[22]. The first trial of each velocity was excluded from
analyses. To determine the average resistance to stretch
for an entire trial, the work done on the dynamometer
was calculated by determining the area under the gravitycorrected torque versus angle curve. To exclude end
effects caused by the dynamometer, the boundaries of the
area were set at 5, 30, the torque curve, and the zero
torque line. Work can be calculated using the formula
Equation 1:



30

5

T  d

,

(1)

where T = the torque produced against the dynamometer
and dθ = a small change in the angle (Figure 1) [10]. The

Figure 1.
Work was calculated by determining area between gravitycorrected torque versus angle curve and zero torque. To
exclude end effects, boundaries of area were set at 5, 30,
torque curve, and zero torque line. Work can be calculated
using the equation, where T = torque produced against dynamometer and dθ = small change in angle.
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average work was calculated for each individual at each
velocity tested. Linear regression was used to determine
the slope of the line of best fit for the average work as a
function of velocity (Figure 2). This slope has been
shown to be a quantitative measure of spasticity in that it
represents a velocity-dependent resistance to passive
stretch [10]. The maximum slope value calculated for

each participant was used for subsequent analysis (PF
Max DSM).
Statistical Analysis
Statistical analyses were performed in SPSS version
20 (IBM Corporation; Armonk, New York). Significance
was accepted at p < 0.05. Since distributions were not nor-

Figure 2.
Raw data for person with multiple sclerosis (a) with clinically assessed spasticity (plantarflexor modified Ashworth Scale [PF MAS] =
3) at different velocities, (b) with associated regression line of best fit, (c) with raw data without spasticity (PF MAS = 0) at different
velocities, and (d) with associated regression line of best fit.
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mal, Spearman rho correlations were used to evaluate relationships between spasticity measures (PF Max MAS, PF
Max DSM) and measures of walking speed (T25FWT),
walking endurance (6MWT), and self-perceived
limitations in walking (MSWS-12). Interpretation of the
magnitude of the correlation coefficients were as follows:
weak (r < 0.30), moderate (0.30  r < 0.70), and strong
(r  0.70) [23]. Based on our sample size, correlation
coefficients greater than 0.30 and 0.49 were statistically
significant at the p < 0.05 and p < 0.001 levels,
respectively [24]. Mann-Whitney U tests assessed differences in DSM between pwMS with a MAS  1 and pwMS
with a MAS = 0. The magnitude of the difference between
groups (pwMS with a MAS  1 vs pwMS with a
MAS = 0) was estimated by calculating the Cohen d effect
size [25].

Table 1.
Participant demographics.

Variable
Participants (n)
Age (yr), mean ± SD (range)
BMI, mean ± SD (range)
Female, n (%)
Race, n (%)
Caucasian
African American
EDSS, median (IQR) [range]
Type of MS, n (%)
RR
SP
PP
Time Since Diagnosis (yr),
mean ± SD (range)

Value
42
42.9 ± 10.2 (24–63)
26.7 ± 5.4 (20.4–42.7)
27 (64)
30 (71)
12 (29)
3.0 (2.9–4.8) [0–6]
35 (83)
5 (12)
2 (5)
7.7 ± 6.1 (1–20)

BMI = body mass index, EDSS = Expanded Disability Status Scale, IQR =
interquartile range, MS = multiple sclerosis, PP = primary progressive, RR =
relapsing-remitting, SD = standard deviation, SP = secondary progressive.

RESULTS
Three participants were excluded from data analysis
because their dynamometer data could not be processed:
one participant due to an extremely limited DF ROM and
two participants because the ankle was unable to be passively rotated due to ankle clonus or leg spasms confirmed
by visual inspection of EMG. Table 1 provides demographics and clinical characteristics of the remaining
participants (n = 42). Based on median EDSS scores, our
sample of pwMS had mild clinical disability [26]. Of the
participants, 12 (29%) reported using a straight cane for
community ambulation. Seven (17%) pwMS used a cane
during the T25FWT. Nine (21%) pwMS used a cane during the 6MWT. Three of these participants wore a unilateral ankle-foot orthosis during testing. Six (14%) pwMS
reported the use of oral antispasticity medications.
Our sample of pwMS had mild PF spasticity based
on the PF Max MAS and PF Max DSM values (Table 2)
[27]. Of the participants, 69 percent (29/42) were classified as having clinically assessed spasticity based on a PF
MAS score  1 on either leg. The PF Max MAS and the
PF Max DSM were measured in the same limb in 90 percent (38/42) of participants. PF Max DSM values did not
differ between pwMS with a MAS  1 and pwMS with a
MAS = 0 (0.0040 ± 0.0015 vs 0.0037 ± 0.0012, p = 0.38,
d = 0.23). There was a weak relationship between the
clinically assessed measures and DSMs of PF spasticity
(PF Max MAS vs PF Max DSM: ρ = 0.260, p = 0.10).

Our sample of pwMS had mild to moderate limitations
in walking speed and endurance [17,28] and self-perceived
limitations in walking (Table 2). Regardless of the
method, PF spasticity weakly correlated with the T25FWT
(PF Max MAS: ρ = 0.27, p = 0.08; PF Max DSM: ρ =
0.26, p = 0.10), 6MWT (PF Max MAS: ρ = 0.20, p =
0.20; PF Max DSM: ρ = 0.21, p = 0.18), and MSWS12
(PF Max MAS: ρ = 0.11, p = 0.48; PF Max DSM: ρ = 0.26,
p = 0.09).

DISCUSSION
The major finding of this study is that PF spasticity
has a limited association with walking speed, walking
endurance, and self-perceived walking limitations in
pwMS with mild clinical disability, regardless of whether
spasticity was measured clinically or using a dynamometer. The DSM confirmed our previous report of a weak
association between clinically assessed PF spasticity and
walking dysfunction in this cohort of pwMS [8]. Our
results are consistent with reports in other neurologic clinical populations, wherein spasticity quantified with clinical
scales or instrumented measures has a limited association
with walking dysfunction [29–32]. The poor association
found between PF spasticity and walking dysfunction may
help explain the limited efficacy of spasticity management
for improving walking in pwMS [33–34], at least in pwMS
with mild spasticity and clinical disability.
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Table 2.
Spasticity and walking measures for persons with multiple sclerosis (n = 42).

Measure
PF Max MAS (score)
PF Max DSM (J/[/s])
T25FWT (s)
6MWT (m)
MSWS-12 (score)

Mean
1.43
0.0039
5.84
466.7
42.9

Standard Deviation
1.33
0.0014
2.30
133.9
22.3

Range
0–4
0.0022–0.0096
3.68–14.8
157.9–677.0
0–90.5

PF Max MAS (score)

Median
1

Interquartile Range
0–2

Range
0–4

6MWT = 6-minute walk test, DSM = dynamometer-based spasticity measure, MAS = modified Ashworth Scale, Max = maximum, MSWS-12 = 12-item Multiple
Sclerosis Walking Scale, PF = plantarflexor, T25FWT = timed 25-foot walk test.

Self-reported walking difficulties become more common and more pronounced in pwMS as the severity of
self-reported spasticity increases [5,35]. It is possible that
the weak association found between PF spasticity and
self-reported walking dysfunction in our cohort of pwMS
is due to the low levels of spasticity in our cohort of
pwMS. A stronger association might exist between PF
spasticity, quantified using the MAS or DSM, and selfreported walking dysfunction in pwMS with more severe
PF spasticity or in pwMS exhibiting clonus.
Our results differ from a report on pwMS where
those with PF spasticity were found to have greater
mobility impairment than those without PF spasticity [7].
In Sosnoff et al., the spasticity group had considerably
greater clinical disability than the no spasticity group [7].
The association between PF spasticity and mobility
impairment was not reported. In our cohort, clinical disability was similar between the spasticity and no spasticity groups. We have previously reported no differences in
walking between the groups [8]. Because the level of PF
spasticity was similar in both studies, it is possible that
additional impairments contributing to overall disability
(i.e., weakness, sensory loss, and ataxia) may have contributed to the group differences in mobility reported by
Sosnoff et al. [7].
The weak association between the MAS and DSM in
our cohort of ambulatory pwMS is congruent with
reports in other neurologic clinical populations, demonstrating a limited association between clinical and instrumented measures of upper- and lower-limb spasticity
[10,13–14,36]. Collectively, these results suggest that the
MAS and DSM may quantify different components of
spasticity. The MAS quantifies “increase in muscle
tone,” which may be due to both reflex and nonreflex
components of resistance to passive movement [6]. The

DSM quantifies the change in work at different velocities. The nonreflex component (e.g., stiffness) of resistance to passive movement should be similar at different
velocities. Therefore, we believe the DSM primarily
quantifies the reflex component of resistance to passive
stretch. Our study design does not allow us to determine
the unique contribution of the nonreflex component of
spasticity [37]. Differences in participant positioning for
the two measures may also contribute to the weak association between clinical and instrumented measures. Additionally, the limited range of MAS scores in our cohort of
ambulatory pwMS may have attenuated the relationship
between the MAS and DSM [14].
The median MAS score for the spasticity group was
slightly larger than the median MAS score for the no
spasticity group. Consistent with the MAS, the average
DSM value for pwMS with clinically assessed PF spasticity was slightly larger than the value for pwMS without clinically assessed PF spasticity. The DSM values for
pwMS with a MAS  1 and pwMS with a MAS = 0 were
similar to the PF DSM value reported for children without disability [8]. Thus, the DSM confirmed the mild
severity of clinically assessed PF spasticity in our cohort
of ambulatory pwMS with mild disability.
The current study has limitations. First, pwMS in this
investigation had low levels of clinical spasticity; therefore, the results may not generalize to ambulatory pwMS
with more pronounced clinical spasticity. Second, pwMS
exhibiting clonus or muscle spasms during the DSM
were excluded from analyses because it invalidated our
algorithm for processing velocity-dependent resistance to
passive stretch. Third, the ROM during the DSM was
truncated due to the deceleration artifact of the dynamometer. Thus, the DSM did not evaluate spasticity over
the entire ROM. Fourth, because reflexes depend on the
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specific task and limb positioning [38], spasticity measured in the semisupine position may not be equivalent to
spasticity measured during ambulation. Fifth, spasticity
was only evaluated at the ankle; we are unable to determine whether, and to what extent, spasticity of other
muscle groups contribute to walking dysfunction in
pwMS. Finally, our study was not designed to investigate
the contribution of other lower-limb impairments to
walking dysfunction.

CONCLUSIONS
PF spasticity has a limited association with walking
speed, walking endurance, and self-perceived walking
limitations in pwMS with mild clinical disability, regardless of whether spasticity was measured clinically using
the MAS or using a dynamometer. The weak association
between the DSM and the MAS suggests that the two
tests may quantify different components of spasticity.
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